JOP20220092A1 - جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر - Google Patents

جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر

Info

Publication number
JOP20220092A1
JOP20220092A1 JOP/2022/0092A JOP20220092A JOP20220092A1 JO P20220092 A1 JOP20220092 A1 JO P20220092A1 JO P20220092 A JOP20220092 A JO P20220092A JO P20220092 A1 JOP20220092 A1 JO P20220092A1
Authority
JO
Jordan
Prior art keywords
beta
disease
treating alzheimer
amyloid antibody
amyloid
Prior art date
Application number
JOP/2022/0092A
Other languages
Arabic (ar)
English (en)
Inventor
Edward Plowey
Haeberlein Samantha Budd
Thierry Bussiere
John Beaver
Ying Tian
Gersham Dent
Raj Rajagovindan
Roger Nitsch
Laura Nisenbaum
Original Assignee
Biogen Ma Inc
Neurimmune Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc, Neurimmune Ag filed Critical Biogen Ma Inc
Publication of JOP20220092A1 publication Critical patent/JOP20220092A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JOP/2022/0092A 2019-10-22 2022-04-20 جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر JOP20220092A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924633P 2019-10-22 2019-10-22
PCT/US2020/056676 WO2021081101A1 (en) 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
JOP20220092A1 true JOP20220092A1 (ar) 2023-01-30

Family

ID=73344157

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0092A JOP20220092A1 (ar) 2019-10-22 2022-04-20 جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر

Country Status (13)

Country Link
US (1) US20220372123A1 (https=)
EP (1) EP4048695A1 (https=)
JP (2) JP2022553329A (https=)
KR (1) KR20220084095A (https=)
CN (1) CN114599393A (https=)
AU (1) AU2020371612A1 (https=)
BR (1) BR112022007595A2 (https=)
CA (1) CA3158513A1 (https=)
CO (1) CO2022004902A2 (https=)
IL (1) IL292363A (https=)
JO (1) JOP20220092A1 (https=)
MX (1) MX2022004678A (https=)
WO (1) WO2021081101A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2019152706A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a6a antibodies and methods of use thereof
US11472874B2 (en) 2018-01-31 2022-10-18 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2023081194A2 (en) * 2021-11-03 2023-05-11 Biogen Ma Inc. Methods for treating alzheimer's disease
AU2022439338A1 (en) * 2022-02-02 2024-08-15 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
WO2024086796A1 (en) * 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
US20240207362A1 (en) * 2022-10-25 2024-06-27 Institute For Basic Science (Ibs) Extracranial Methods For Facilitating Cerebrospinal Fluid Drainage
EP4455161A1 (en) 2023-04-24 2024-10-30 ONO Pharmaceutical Co., Ltd. Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies
TW202530246A (zh) 2023-09-15 2025-08-01 愛爾蘭商歐賽爾普羅希那有限公司 細胞穿透劑及其用途
WO2025117721A1 (en) * 2023-11-27 2025-06-05 Massachusetts Institute Of Technology Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
WO2008141321A1 (en) * 2007-05-14 2008-11-20 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2598882B1 (en) * 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
ME03008B (me) * 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
US20150315267A1 (en) * 2012-12-07 2015-11-05 Thierry Bussiere A method of reducing brain amyloid plaques using anti-ab antibodies
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN114796481A (zh) * 2016-06-07 2022-07-29 生物基因国际神经科学有限责任公司 治疗阿尔茨海默病的方法

Also Published As

Publication number Publication date
WO2021081101A1 (en) 2021-04-29
IL292363A (en) 2022-06-01
AU2020371612A1 (en) 2022-05-19
CA3158513A1 (en) 2021-04-29
JP2026012271A (ja) 2026-01-23
CO2022004902A2 (es) 2022-07-08
BR112022007595A2 (pt) 2022-08-23
KR20220084095A (ko) 2022-06-21
CN114599393A (zh) 2022-06-07
EP4048695A1 (en) 2022-08-31
US20220372123A1 (en) 2022-11-24
MX2022004678A (es) 2022-08-15
JP2022553329A (ja) 2022-12-22

Similar Documents

Publication Publication Date Title
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
ZA202107358B (en) Method for treating alzheimer's disease
MX2021002321A (es) Nuevos metodos.
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
EA201892190A1 (ru) Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
MY184890A (en) Improved a? protofibril binding antibodies
EP4378524A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
MY187358A (en) Modified release orally administered amino acid formulations
MX2018015022A (es) Métodos para el tratamiento de la enfermedad de alzheimer.
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
WO2017142895A8 (en) Compositions and methods for treating clostridium associated diseases
AR119159A1 (es) Tratamientos de angioedema
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
MY206426A (en) Anti-cd38 antibodies and formulations
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
EP4461361A3 (en) Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease
PH12022550254A1 (en) MICROMOLECULE PI4KIIIa INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
MX2025015454A (es) Formulaciones/composiciones que comprenden ibrutinib
WO2020092533A3 (en) Methods of treatment using anti-cd123 immunoconjugates
MX2020007627A (es) Uso de la carrimicina o de sus ingredientes activos.